(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 177.09% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Nyxoah Sa's revenue in 2024 is $4,726,086.On average, 4 Wall Street analysts forecast NYXH's revenue for 2024 to be $267,671,650, with the lowest NYXH revenue forecast at $226,237,742, and the highest NYXH revenue forecast at $295,342,046. On average, 4 Wall Street analysts forecast NYXH's revenue for 2025 to be $1,256,551,371, with the lowest NYXH revenue forecast at $844,448,858, and the highest NYXH revenue forecast at $1,559,004,564.
In 2026, NYXH is forecast to generate $3,053,091,227 in revenue, with the lowest revenue forecast at $2,420,944,554 and the highest revenue forecast at $3,628,406,062.